A Study of the 20 Day Superorbital Modulation in the High-Mass X-ray Binary IGR J16493-4348

We report on Nuclear Spectroscopic Telescope Array (NuSTAR), Neil Gehrels Swift Observatory (Swift) X-ray Telescope (XRT) and Swift Burst Alert Telescope (BAT) observations of IGR J16493-4348, a wind-fed Supergiant X-ray Binary (SGXB) showing significant superorbital variability. From a discrete Fourier transform of the BAT light curve, we refine its superorbital period to be 20.058 $\pm$ 0.007 days. The BAT dynamic power spectrum and a fractional root mean square analysis both show strong variations in the amplitude of the superorbital modulation, but no observed changes in the period were found. The superorbital modulation is significantly weaker between MJD 55,700 and MJD 56,300. The joint NuSTAR and XRT observations, which were performed near the minimum and maximum of one cycle of the 20 day superorbital modulation, show that the flux increases by more than a factor of two between superorbital minimum and maximum. We find no significant changes in the 3-50 keV pulse profiles between superorbital minimum and maximum, which suggests a similar accretion regime. Modeling the pulse-phase averaged spectra we find a possible Fe K$\alpha$ emission line at 6.4 keV at superorbital maximum. The feature is not significant at superorbital minimum. While we do not observe any significant differences between the pulse-phase averaged spectral continua apart from the overall flux change, we find that the hardness ratio near the broad main peak of the pulse profile increases from superorbital minimum to maximum. This suggests the spectral shape hardens with increasing luminosity. We discuss different mechanisms that might drive the observed superorbital modulation.Comment: 17 pages, 14 figures, 3 tables, accepted for publication in The Astrophysical Journal on 2019 May 1

Landsat 9 Thermal Infrared Sensor 2 Subsystem-Level Spectral Test Results

Results from the Thermal Infrared Sensor 2 (TIRS-2) prelaunch spectral characterization at telescope and detector subsystem level are presented. The derived relative spectral response (RSR) shape is expected to be very similar to the instrument-level spectral response and provides an initial estimate of the RSR and its differences to the component-level RSR measurements. Such differences were observed at TIRS- 1 and are likely a result of angular dependence of the spectral response of the detector. The subsystem RSR measurements also provide an opportunity for a preliminary assessment of the spectral requirements. Final requirements verification will be performed at future thermal vacuum environmental testing with the fully assembled TIRS-2 instrument

LANDSAT 9 Thermal Infrared Sensor 2 Characterization Plan Overview

Landsat 9 will continue the Landsat data record into its fifth decade with a near-copy build of Landsat 8 with launch scheduled for December 2020. The two instruments on Landsat 9 are Thermal Infrared Sensor-2 (TIRS-2) and Operational Land Imager-2 (OLI-2). TIRS-2 is a two-channel pushbroom imager with a 15-degree field of view that will have a 16-day measurement cadence from its nominal 705-km orbit altitude. Its carefully developed instrument performance requirements and associated characterization plan will result in stable and well-understood science-quality imagery that will be used for environmental, economic and legal applications. This paper will present a summary of the plan for TIRS-2 prelaunch characterization at the component, subsystem, and instrument level

Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency.

Objective: To investigate associations between peripheral innate immune activation and frontotemporal lobar degeneration (FTLD) in progranulin gene (GRN) haploinsufficiency. Methods: In this cross-sectional study, ELISA was used to measure six markers of innate immunity (sCD163, CCL18, LBP, sCD14, IL-18, and CRP) in plasma from 30 GRN mutation carriers (17 asymptomatic, 13 symptomatic) and 29 controls. Voxel based morphometry was used to model associations between marker levels and brain atrophy in mutation carriers relative to controls. Linear regression was used to model relationships between plasma marker levels with mean frontal white matter integrity [fractional anisotropy (FA)] and the FTLD modified Clinical Dementia Rating Scale sum of boxes score (FTLD-CDR SB). Results: Plasma sCD163 was higher in symptomatic GRN carriers [mean 321 ng/ml (SD 125)] compared to controls [mean 248 ng/ml (SD 58); p < 0.05]. Plasma CCL18 was higher in symptomatic GRN carriers [mean 56.9 pg/ml (SD 19)] compared to controls [mean 40.5 pg/ml (SD 14); p < 0.05]. Elevation of plasma LBP was associated with white matter atrophy in the right frontal pole and left inferior frontal gyrus (p FWE corrected <0.05) in all mutation carriers relative to controls. Plasma LBP levels inversely correlated with bilateral frontal white matter FA (R2 = 0.59, p = 0.009) in mutation carriers. Elevation in plasma was positively correlated with CDR-FTLD SB (b = 2.27 CDR units/μg LBP/ml plasma, R2 = 0.76, p = 0.003) in symptomatic carriers. Conclusion: FTLD-GRN is associated with elevations in peripheral biomarkers of macrophage-mediated innate immunity, including sCD163 and CCL18. Clinical disease severity and white matter integrity are correlated with blood LBP, suggesting a role for peripheral immune activation in FTLD-GRN

Landsat 9 TIRS-2 Performance Results Based on Subsystem-Level Testing

Landsat 9 is the next in the series of Landsat satellites and has a complement of two pushbroom imagers: Operational Land Imager-2 (OLI-2) that samples the solar reflective spectrum with nine channels and Thermal Infrared Sensor-2 (TIRS-2) samples the thermal infrared spectrum with two channels. The first builds of these sensors, OLI and TIRS, were launched on Landsat 8 in 2013 and Landsat 9 is expected to launch in December 2020. TIRS-2 is designed and built to continue the Landsat data record and satisfy the needs of the remote sensing community. There are two sets of requirements considered for planning the component, subsystem and instrument level tests for TIRS-2: performance requirements and Special Calibration Test Requirements (SCTR). The performance requirements specify key spectral, spatial, radiometric, and operational parameters of TIRS-2 while the SCTRs specify parameters of how the instrument is tested. Several requirements can only be verified at the instrument level, but many performance metrics can be assessed earlier in prelaunch testing at the subsystem level. A test program called TIRS Imaging Performance and Cryoshell Evaluation (TIPCE) was developed to characterize TIRS-2 spectral, spatial, and scattered-light rejection performance at the telescope and detector subsystem level. There were three thermal vacuum campaigns in TIPCE that occurred from November 2017 to March 2018. This work shows results of TIPCE data analysis which provide confidence that key requirements will be met at instrument level with a few minor waivers. A full complement of performance testing will be done at the TIRS-2 instrument level for final verification in late 2018 through Spring 2019

Landsat 9 Thermal Infrared Sensor 2 Architecture and Design

The Thermal Infrared Sensor 2 (TIRS-2) will fly aboard the Landsat 9 spacecraft and leverages the Thermal Infrared Sensor (TIRS) design currently flying on Landsat 8. TIRS-2 will provide similar science data as TIRS, but is not a buildto-print rebuild due to changes in requirements and improvements in absolute accuracy. The heritage TIRS design has been modified to reduce the influence of stray light and to add redundancy for higher reliability over a longer mission life. The TIRS-2 development context differs from the TIRS scenario, adding to the changes. The TIRS-2 team has also learned some lessons along the way

Randomized Controlled Trial of Fish Oil and Montelukast and Their Combination on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction

Both fish oil and montelukast have been shown to reduce the severity of exercise-induced bronchoconstriction (EIB). The purpose of this study was to compare the effects of fish oil and montelukast, alone and in combination, on airway inflammation and bronchoconstriction induced by eucapnic voluntary hyperpnea (EVH) in asthmatics. In this model of EIB, twenty asthmatic subjects with documented hyperpnea-induced bronchoconstriction (HIB) entered a randomized double-blind trial. All subjects entered on their usual diet (pre-treatment, n = 20) and then were randomly assigned to receive either one active 10 mg montelukast tablet and 10 placebo fish oil capsules (n = 10) or one placebo montelukast tablet and 10 active fish oil capsules totaling 3.2 g EPA and 2.0 g DHA (n = 10) taken daily for 3-wk. Thereafter, all subjects (combination treatment; n = 20) underwent another 3-wk treatment period consisting of a 10 mg active montelukast tablet or 10 active fish oil capsules taken daily. While HIB was significantly inhibited (p0.017) between treatment groups; percent fall in forced expiratory volume in 1-sec was −18.4±2.1%, −9.3±2.8%, −11.6±2.8% and −10.8±1.7% on usual diet (pre-treatment), fish oil, montelukast and combination treatment respectively. All three treatments were associated with a significant reduction (p0.017) in these biomarkers between treatments. While fish oil and montelukast are both effective in attenuating airway inflammation and HIB, combining fish oil with montelukast did not confer a greater protective effect than either intervention alone. Fish oil supplementation should be considered as an alternative treatment for EIB

Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations

Polygenic risk scores (PRS) have great potential to guide precision colorectal cancer (CRC) prevention by identifying those at higher risk to undertake targeted screening. However, current PRS using European ancestry data have sub-optimal performance in non-European ancestry populations, limiting their utility among these populations. Towards addressing this deficiency, we expand PRS development for CRC by incorporating Asian ancestry data (21,731 cases; 47,444 controls) into European ancestry training datasets (78,473 cases; 107,143 controls). The AUC estimates (95% CI) of PRS are 0.63(0.62-0.64), 0.59(0.57-0.61), 0.62(0.60-0.63), and 0.65(0.63-0.66) in independent datasets including 1681-3651 cases and 8696-115,105 controls of Asian, Black/African American, Latinx/Hispanic, and non-Hispanic White, respectively. They are significantly better than the European-centric PRS in all four major US racial and ethnic groups (p-values < 0.05). Further inclusion of non-European ancestry populations, especially Black/African American and Latinx/Hispanic, is needed to improve the risk prediction and enhance equity in applying PRS in clinical practice